Stock listing

NASDAQ:SPRB Spruce Biosciences, Inc. Stock

Home listing (NASDAQ) of Spruce Biosciences, Inc.

Follow Spruce Biosciences, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:SPRB

$38.00 USD -2.84 (-7.0%)

Close on Nov 20, 2026

Past year -63.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$38.00 – $40.96 USDNov 20, 2026
Volume
108,276 sharesNov 20, 2026
Market cap
$109.2M USDAt the close on Nov 20, 2026 · price × 2.87M shares outstanding
52-week range
$38.00 – $112.26 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$4.40M USDMedian day 83,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Spruce Biosciences, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:SPRB · Home$38.00 USD-2.84 (-7.0%)108,276$39.97$40.96$38.00$40.84Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SPRB · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$38.00-2.84-7.0%$39.97$40.96$38.00108,276
$40.84+0.35+0.9%$41.92$41.92$39.9163,334
$40.49-1.76-4.2%$41.14$41.80$39.98152,243
$42.25-1.06-2.4%$45.04$45.04$41.56102,928
$43.31+0.42+1.0%$42.94$43.38$41.4138,864
$42.89-3.31-7.2%$46.00$46.00$42.0946,002
$46.20-0.465-1.0%$47.00$47.37$45.4450,234
$46.67-2.675-5.4%$48.30$48.30$44.7472,442
$49.34+2.79+6.0%$45.10$51.29$41.00136,237
$46.55+3.84+9.0%$42.95$46.80$42.9563,697
$42.71-3.90-8.4%$46.15$46.58$42.5056,165
$46.61+3.80+8.9%$44.43$46.61$44.4351,951
$42.81-1.74-3.9%$45.00$45.27$42.5173,480
$44.55-1.84-4.0%$46.40$46.99$43.7890,535
$46.39-0.43-0.9%$46.11$46.62$44.6965,958
$46.82-0.17-0.4%$47.50$49.85$46.51104,183
$46.99+1.34+2.9%$45.65$47.25$45.6558,802
$45.65+1.66+3.8%$44.54$46.90$44.0191,553
$43.99-1.16-2.6%$45.47$45.47$43.6266,476
$45.15-0.85-1.8%$45.80$46.10$43.3473,800
$46.00+3.27+7.7%$42.58$46.25$42.51126,500
$42.73+1.50+3.6%$41.00$42.73$40.8261,500
$41.23+0.83+2.1%$40.57$42.65$40.4052,500
$40.40+0.75+1.9%$39.97$41.00$39.2557,100
$39.65-1.82-4.4%$41.53$41.84$39.2188,400
$41.47+2.49+6.4%$39.00$41.88$39.0063,800
$38.98-1.37-3.4%$40.00$41.44$38.06112,700
$40.35-2.52-5.9%$42.80$42.91$40.19110,600
$42.87-1.18-2.7%$44.09$44.94$42.5574,900
$44.05-1.49-3.3%$44.84$45.04$42.8083,800
$45.54+1.14+2.6%$43.50$45.65$43.3450,800
$44.40+1.615+3.8%$42.56$45.40$42.3759,700
$42.79-2.635-5.8%$45.60$46.72$42.50101,900
$45.42-0.29-0.6%$45.51$46.80$43.8365,100
$45.71+0.94+2.1%$46.58$47.73$44.1377,200
$44.77-3.81-7.8%$48.15$49.20$44.4779,600
$48.58+1.31+2.8%$47.78$49.95$47.7661,300
$47.27-0.24-0.5%$47.55$48.00$46.5584,200
$47.51-1.21-2.5%$48.28$48.99$47.0142,400
$48.72-0.30-0.6%$49.22$49.31$47.5437,200
$49.02-0.395-0.8%$49.01$49.50$47.5885,800
$49.42-0.575-1.2%$50.50$50.74$45.01174,800
$49.99-3.71-6.9%$54.05$54.98$49.23140,700
$53.70+0.65+1.2%$53.84$55.06$53.0796,500
$53.05-0.81-1.5%$53.04$53.86$51.8099,700
$53.86-0.30-0.6%$56.22$57.11$53.28135,300
$54.16-1.005-1.8%$55.01$56.27$53.2696,600
$55.17-1.685-3.0%$55.99$56.36$54.51105,500
$56.85+3.15+5.9%$53.28$57.55$52.66102,600
$53.70-0.65-1.2%$54.78$56.08$53.0988,500
$54.35-1.39-2.5%$55.61$57.50$54.03113,000
$55.74-3.35-5.7%$58.52$59.01$55.7091,900
$59.09+1.16+2.0%$57.39$60.51$56.60193,000
$57.93+0.22+0.4%$57.37$58.19$56.57103,900
$57.71-1.96-3.3%$59.76$60.32$57.30113,500
$59.67+4.07+7.3%$56.52$60.13$56.52268,100
$55.60-3.37-5.7%$58.01$58.05$55.3458,100
$58.97-1.81-3.0%$60.54$60.90$57.5844,900
$60.78-2.52-4.0%$62.12$62.98$59.9040,000
$63.30+1.82+3.0%$62.00$63.56$60.5580,300
$61.48-1.92-3.0%$64.50$64.50$60.4691,800
$63.40+4.75+8.1%$58.82$64.15$58.00147,298
$58.65+7.07+13.7%$53.04$58.92$51.16138,812
$51.58-0.405-0.8%$52.48$53.00$49.0362,300
$51.99-0.975-1.8%$52.83$52.89$50.5021,600

Splits

1 split · NASDAQ:SPRB · every price before a split is adjusted for it

DayRatioWhat
1-for-75Consolidation
Ticker
NASDAQ:SPRB
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Spruce Biosciences, Inc. news

Spruce Biosciences, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
31 in the last 12 months · 86 in all · newest Nov 9, 2026 · oldest 2020
Decks
4 decks · latest Aug 12, 2026

Where Spruce Biosciences, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:SPRB · Home listing · This pageNASDAQUnited StatesUSD
BOATS:SPRBBOATSUnited StatesUSD

Valuation

Price/book 1.6× against a median of 2.0×: 5th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$41.00M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
1.6×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.3×
Beta vs S&P 500
1.73

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Spruce Biosciences, Inc. · NASDAQ:SPRBUS$109.2MUS$41.00Mn/an/an/a1.6×n/a0.3×1.73
Sinew Pharma, Inc. · TPEX:6634US$114.4MUS$84.23Mn/a59,064×n/a3.6×n/a0.0×n/a
Armata Pharmaceuticals, Inc. · AMEX:ARMPUS$112.7MUS$346.0Mn/a45.8×n/an/an/an/a0.97
Medigen Biotechnology Corporation · TPEX:3176US$111.8MUS$61.95Mn/a1.6×n/a2.5×−19.9%0.8×n/a
Fate Therapeutics, Inc. · NASDAQ:FATEUS$111.7MUS$47.08Mn/a9.9×n/a0.8×n/a0.6×2.25
OnKure Therapeutics, Inc. · NASDAQ:OKURUS$109.4M−US$53.16Mn/an/an/a0.7×n/a0.0×1.17
NIBEC Co., Ltd. · KRX:138610US$108.7MUS$92.50Mn/a5.5×118×3.0×−0.1%0.0×n/a
Jyong Biotech Ltd. · NASDAQ:MENSUS$107.6MUS$125.0Mn/an/an/an/an/an/a1.74
Nykode Therapeutics ASA · OSL:NYKDUS$107.0MUS$62.24Mn/an/an/a1.3×n/a0.0×n/a
JW (Cayman) Therapeutics Co. Ltd. · HKEX:2126US$105.3MUS$84.72Mn/a2.0×n/a1.6×−195.8%0.6×n/a
Genelux Corporation · NASDAQ:GNLXUS$104.3MUS$93.85Mn/a11,732×n/a11.4×n/a0.0×1.52
Median of the othersUS$109.0MUS$84.47M9.9×118×2.0×−19.9%0.0×1.52

Forecasts

8 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
147.89 USD · Analysts' mean
EPS, year to Dec 2026
-25.80 · 8 analysts

Team and board

Officers

OfficerRole
Javier SzwarcbergChief Executive Officer
Samir GharibPresident and Chief Financial Officer
Tina GullottaVice President, Finance and Corporate Controller
Agnieszka AJ JureckaVice President, Medical Affairs
Brian WallsVice President, Market Access
Bruno GagnonSenior Vice President, Clinical Development Operations
Darren JohnsonVice President, Commercial Operations
Dash ReddyVice President, Pharmaceutical Development and Manufacturing
Daven ModySenior Vice President, Regulatory and Quality
Eric JordanVice President, Marketing
Jessica Cohen PfefferVice President, Clinical Development
Saba SileSenior Vice President, Clinical Development
Adrian QuartelChief Medical Officer
Dale HooksChief Commercial Officer
Michael GreyExecutive Chairman

Board

DirectorRole
Michael GreyExecutive Chairman
Camilla V. SimpsonIndependent
Dan SpiegelmanIndependent
Javier SzwarcbergChief Executive Officer
Keli WalbertIndependent
Kirk Ways
Percival Barretto-KoIndependent

Events

QuarterResultsShare move
Q3 2026Nov 9, 2026 · Before open+6.0%
Q2 2026Aug 12, 2026 · Before open+1.4%
Q1 2026May 13, 2026 · Before open+1.6%
Q4 2025Mar 9, 2026+12.4%
Q3 2025Nov 10, 2025 · After close−2.5%
Q2 2025Aug 14, 2025 · After close+3.0%
Q1 2025Apr 15, 2025 · Before open−58.0%
Q4 2024Mar 12, 2025−4.8%
Q3 2024Nov 12, 2024 · Before open−1.3%
Q2 2024Aug 12, 2024 · After close+3.9%
All 20 quarters
QuarterResultsShare move
Q1 2024May 13, 2024 · After close+2.5%
Q4 2023Mar 13, 2024 · After close−84.4%
Q3 2023Nov 13, 2023 · After close−3.7%
Q2 2023Aug 14, 2023 · After close−1.4%
Q1 2023May 15, 2023 · Before open−2.2%
Q4 2022Mar 16, 2023 · After close+1.3%
Q3 2022Nov 10, 2022 · After close+10.5%
Q2 2022Aug 10, 2022 · After close+3.6%
Q1 2022May 11, 2022 · After close+1.6%
Q4 2021Mar 14, 2022 · After close−1.6%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (August 2026)Investor deck22 slidesAug 12, 2026
Corporate Update (April 2025)Corporate update15 slidesApr 15, 2025
Baird 2021 Global Healthcare ConferenceConference17 slidesSep 15, 2021
Investor Day (August 2021)Investor day68 slidesAug 25, 2021

Open Decks

Financings

RaiseDate
Strategic investment
Announced: US$5.5M
Buyers: Cure Sanfilippo Foundation (part of a combined $5.5 million strategic investment); National MPS Society (part of a combined $5.5 million strategic investment)
Use of proceeds: Partially fund the TA-ERT Expanded Access Program to broaden patient access to TA-ERT for Sanfilippo Syndrome Type B
Aug 12, 2026
Public offering of common stock or pre-funded warrants
Announced: Leerink Partners +4
Dealers: Leerink Partners (co-lead), Guggenheim Securities (co-lead), Oppenheimer & Co. (co-lead), Jones, Craig-Hallum
Apr 20, 2026
Private placement of common stock and pre-funded warrants
Announced: about US$50M · US$68 a share · Leerink Partners +3
Dealers: Leerink Partners, Citizens Capital Markets, H.C. Wainwright & Co., Oppenheimer & Co.
Use of proceeds: Advance tralesinidase alfa (TA-ERT) for Sanfilippo Syndrome Type B through a BLA submission in Q1 2026 and potential U.S. launch in late 2026
Oct 8, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$15.00 a share on Oct 8, 2020.

Price
US$15.00 a share
Shares offered
6,000,000 shares of common stock
Offering size
US$90 million
Underwriters' option
Up to 900,000 more shares
Underwriters
Cowen, SVB Leerink, Credit Suisse, RBC Capital Markets · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceAug 7, 2020
Filed publiclySep 18, 2020
Amended onceOct 5, 2020
Shares registered with an exchangeOct 5, 2020
Declared effective by the SECOct 8, 2020
Final prospectus, with the priceOct 9, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Oct 9, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue04.91M10.1M00000
Cost of revenue21.0K49.4M429.0K381.0K102.0K12.0K1.00K
Gross profit-21.0K4.91M10.1M-429.0K-381.0K-102.0K-12.0K-1.00K
Research and development19.5M46.4M49.4M35.2M30.7M23.9M10.8M8.40M
Selling, general and administrative17.0M14.6M12.7M12.1M11.4M5.56M2.29M1.57M
Operating income-36.5M-56.2M-52.0M-47.3M-42.1M-29.4M-13.1M-9.97M
Depreciation and amortization21.0K46.0K70.0K74.0K68.0K36.0K12.0K1.00K
EBITDA-36.5M-56.1M-51.9M-47.2M-42.0M-29.4M-13.1M-9.97M
Interest expense90.0K307.0K483.0K420.0K345.0K323.0K65.0K0
Income before tax-39.0M-53.0M-47.9M-46.2M-42.3M-29.5M-13.1M-9.86M
Income tax0000000114.0K
Net income-39.0M-53.0M-47.9M-46.2M-42.3M-29.5M-13.1M-9.86M
Earnings per share, basic-50.83-96.40-1.24-1.96-1.81-4.93-17.12-496.00
Earnings per share, diluted-50.83-96.40-1.24-1.96-1.81-4.93-17.12

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents48.9M38.8M96.3M24.5M42.7M157.2M3.92M4.11M
Short-term investments054.6M46.2M0
Receivables0
Current assets52.1M44.2M102.2M83.6M91.9M160.4M4.65M4.77M
Property, plant and equipment1.40M140.0K73.0K
Total assets53.0M45.2M103.9M85.6M126.5M162.9M4.69M4.78M
Accounts payable943.0K1.29M3.33M1.43M2.82M3.63M1.88M2.30M
Current liabilities10.1M15.2M24.5M12.4M8.87M9.76M4.30M2.71M
Long-term debt0124.0K1.72M3.29M4.88M1.92M3.19M
Total debt01.84M3.71M5.64M4.88M4.48M4.45M
Total liabilities10.5M16.4M27.4M17.2M15.1M13.5M7.52M22.6M
Shareholders' equity42.5M28.8M76.5M68.5M111.4M149.4M-30.6M-17.8M
Shares outstanding1.37M563.0K41.0M23.6M23.5M23.3M764.4K19.9K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-33.3M-56.0M-33.3M-41.7M-35.9M-27.5M-12.6M-8.57M
Capital spending00-7.00K-8.00K-93.0K-74.0K-4.00K-4.00K
Free cash flow-33.3M-56.0M-33.3M-41.7M-36.0M-27.6M-12.6M-8.57M
Cash from investing055.8M23.7M-79.2M-74.0K-4.00K-4.00K
Cash from financing43.5M-1.62M49.1M-241.0K643.0K181.0M12.4M12.4M
Dividends paid-169.0K-423.0K
Share buybacks25.0K66.0K-311.0K-40.0K134.0K93.4M
Change in cash10.2M-57.6M71.6M-18.2M-114.4M153.4M-188.0K-8.57M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 9, 2026Quarterly reportSEC
8-K · Current reportNov 9, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 12, 2026Quarterly reportSEC
8-K · Current reportAug 12, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 4, 2026Big-stake noticeSEC
Show 200 filings
FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeJul 30, 2026Big-stake noticeSEC
4 · Change in ownershipJul 29, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 29, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJul 27, 2026Big-stake noticeSEC
8-K · Current reportJul 27, 2026Management or board changeSEC
4 · Change in ownershipJul 9, 2026Insider tradeSEC
4 · Change in ownershipMay 26, 2026Insider tradeSEC
4 · Change in ownershipMay 26, 2026Insider tradeSEC
4 · Change in ownershipMay 26, 2026Insider tradeSEC
4 · Change in ownershipMay 26, 2026Insider tradeSEC
4 · Change in ownershipMay 26, 2026Insider tradeSEC
8-K · Current reportMay 26, 2026Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansMay 13, 2026Offer documentSEC
10-Q · Quarterly reportMay 13, 2026Quarterly reportSEC
8-K · Current reportMay 13, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 7, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeApr 28, 2026Big-stake noticeSEC
8-K · Current reportApr 21, 2026Material contractSEC
424B5 · ProspectusApr 21, 2026Offer documentSEC
424B5 · ProspectusApr 20, 2026Offer documentSEC
ARS · Annual report to shareholdersApr 9, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 9, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 9, 2026Meeting noticeSEC
8-K · Current reportMar 20, 2026Current reportSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 9, 2026Insider tradeSEC
424B5 · ProspectusMar 9, 2026Offer documentSEC
S-8 · Registration statement for employee plansMar 9, 2026Offer documentSEC
8-K · Current reportMar 9, 2026ResultsSEC
10-K · Annual reportMar 9, 2026Annual reportSEC
SCHEDULE 13G · Big-stake noticeFeb 24, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 18, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 10, 2026Big-stake noticeSEC
8-K · Current reportFeb 5, 2026Current reportSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
8-K · Current reportJan 8, 2026ResultsSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipDec 17, 2025Insider tradeSEC
4 · Change in ownershipDec 17, 2025Insider tradeSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
3 · Initial statement of ownershipDec 15, 2025Insider tradeSEC
8-K · Current reportDec 15, 2025Management or board changeSEC
4 · Change in ownershipDec 12, 2025Insider tradeSEC
4 · Change in ownershipDec 12, 2025Insider tradeSEC
424B3 · ProspectusDec 12, 2025Offer documentSEC
8-K · Current reportDec 12, 2025Management or board changeSEC
EFFECT · Notice that a registration is effectiveNov 28, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveNov 28, 2025Other filingsSEC
CORRESP · Letter to the SECNov 24, 2025Other filingsSEC
CORRESP · Letter to the SECNov 24, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeNov 24, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 10, 2025Quarterly reportSEC
8-K · Current reportNov 10, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 7, 2025Big-stake noticeSEC
S-3 · Registration statementOct 29, 2025Offer documentSEC
S-3 · Registration statementOct 29, 2025Offer documentSEC
4 · Change in ownershipOct 22, 2025Insider tradeSEC
4 · Change in ownershipOct 22, 2025Insider tradeSEC
8-K · Current reportOct 17, 2025Management or board changeSEC
DOct 16, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeOct 16, 2025Big-stake noticeSEC
4 · Change in ownershipOct 15, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 15, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeOct 15, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 9, 2025Big-stake noticeSEC
4 · Change in ownershipOct 8, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 8, 2025Insider tradeSEC
8-K · Current reportOct 8, 2025Material contractSEC
SCHEDULE 13G · Big-stake noticeOct 8, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
8-K · Current reportAug 14, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2025Big-stake noticeSEC
4 · Change in ownershipJul 24, 2025Insider tradeSEC
4 · Change in ownershipJul 24, 2025Insider tradeSEC
4 · Change in ownershipJul 24, 2025Insider tradeSEC
4 · Change in ownershipJul 24, 2025Insider tradeSEC
4 · Change in ownershipJul 24, 2025Insider tradeSEC
4 · Change in ownershipJul 24, 2025Insider tradeSEC
4 · Change in ownershipJul 24, 2025Insider tradeSEC
8-K · Current reportJul 24, 2025Meeting outcomeSEC
8-K · Current reportJun 12, 2025Current reportSEC
DEFA14A · Additional proxy materialJun 12, 2025Meeting noticeSEC
DEFA14A · Additional proxy materialJun 6, 2025Meeting noticeSEC
DEFA14A · Additional proxy materialJun 6, 2025Meeting noticeSEC
8-K · Current reportMay 29, 2025Material contractSEC
10-Q · Quarterly reportMay 6, 2025Quarterly reportSEC
8-K · Current reportMay 6, 2025ResultsSEC
ARS · Annual report to shareholdersApr 28, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2025Meeting noticeSEC
8-K · Current reportApr 25, 2025Current reportSEC
PRE 14A · Preliminary proxy statementApr 18, 2025Meeting noticeSEC
S-8 · Registration statement for employee plansApr 15, 2025Offer documentSEC
10-K · Annual reportApr 15, 2025Annual reportSEC
8-K · Current reportApr 15, 2025ResultsSEC
8-K · Current reportApr 1, 2025ResultsSEC
NT 10-K · Late filing noticeMar 31, 2025Explanation requestSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 10, 2025Big-stake noticeSEC
8-K · Current reportDec 27, 2024Management or board changeSEC
4 · Change in ownershipDec 20, 2024Insider tradeSEC
4 · Change in ownershipDec 20, 2024Insider tradeSEC
4 · Change in ownershipDec 20, 2024Insider tradeSEC
8-K · Current reportDec 10, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
8-K · Current reportOct 28, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedOct 23, 2024Big-stake noticeSEC
10-Q · Quarterly reportAug 12, 2024Quarterly reportSEC
8-K · Current reportAug 12, 2024ResultsSEC
8-K · Current reportJun 18, 2024Material contractSEC
8-K · Current reportJun 3, 2024Current reportSEC
4 · Change in ownershipMay 24, 2024Insider tradeSEC
4 · Change in ownershipMay 24, 2024Insider tradeSEC
4 · Change in ownershipMay 24, 2024Insider tradeSEC
4 · Change in ownershipMay 24, 2024Insider tradeSEC
4 · Change in ownershipMay 24, 2024Insider tradeSEC
4 · Change in ownershipMay 24, 2024Insider tradeSEC
4 · Change in ownershipMay 24, 2024Insider tradeSEC
8-K · Current reportMay 24, 2024Meeting outcomeSEC
10-Q · Quarterly reportMay 13, 2024Quarterly reportSEC
8-K · Current reportMay 13, 2024ResultsSEC
8-K · Current reportApr 30, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedApr 25, 2024Big-stake noticeSEC
ARS · Annual report to shareholdersApr 5, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 5, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 5, 2024Meeting noticeSEC
SC 13D/A · Big-stake notice, amendedMar 28, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeMar 28, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedMar 25, 2024Big-stake noticeSEC
4 · Change in ownershipMar 25, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedMar 20, 2024Big-stake noticeSEC
4 · Change in ownershipMar 20, 2024Insider tradeSEC
144 · Notice of proposed saleMar 18, 2024Other filingsSEC
SC 13D/A · Big-stake notice, amendedMar 18, 2024Big-stake noticeSEC
4 · Change in ownershipMar 18, 2024Insider tradeSEC
4 · Change in ownershipMar 18, 2024Insider tradeSEC
4 · Change in ownershipMar 18, 2024Insider tradeSEC
4 · Change in ownershipMar 18, 2024Insider tradeSEC
S-8 · Registration statement for employee plansMar 18, 2024Offer documentSEC
10-K · Annual reportMar 18, 2024Annual reportSEC
144 · Notice of proposed saleMar 14, 2024Other filingsSEC
8-K · Current reportMar 13, 2024ResultsSEC
SC 13D/A · Big-stake notice, amendedMar 7, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 6, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeJan 30, 2024Big-stake noticeSEC
8-K · Current reportJan 8, 2024ResultsSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
4 · Change in ownershipDec 18, 2023Insider tradeSEC
4 · Change in ownershipDec 18, 2023Insider tradeSEC
4 · Change in ownershipDec 18, 2023Insider tradeSEC
4 · Change in ownershipNov 28, 2023Insider tradeSEC
4 · Change in ownershipNov 13, 2023Insider tradeSEC
10-Q · Quarterly reportNov 13, 2023Quarterly reportSEC
8-K · Current reportNov 13, 2023ResultsSEC
10-Q · Quarterly reportAug 14, 2023Quarterly reportSEC
8-K · Current reportAug 14, 2023ResultsSEC
4 · Change in ownershipJul 5, 2023Insider tradeSEC
4 · Change in ownershipJul 5, 2023Insider tradeSEC
4 · Change in ownershipJul 5, 2023Insider tradeSEC
SC 13D/A · Big-stake notice, amendedMay 30, 2023Big-stake noticeSEC
4 · Change in ownershipMay 26, 2023Insider tradeSEC
4 · Change in ownershipMay 26, 2023Insider tradeSEC
4 · Change in ownershipMay 26, 2023Insider tradeSEC
4 · Change in ownershipMay 26, 2023Insider tradeSEC
4 · Change in ownershipMay 26, 2023Insider tradeSEC
4 · Change in ownershipMay 26, 2023Insider tradeSEC
4 · Change in ownershipMay 26, 2023Insider tradeSEC

This page holds 200 of 369 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Spruce Biosciences, Inc.’s releases · as of Nov 5, 2026

Common shares
2,874,013
Fully diluted
2,874,013

Fully diluted

LineSharesAs of
Common shares2,874,013Nov 5, 2026

Share count over time

CountShares
Nov 5, 20262,874,013
Sep 30, 20262,874,013

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
AIGH Capital Management LLC250K8.7%US$12.1MSep 30, 2026
Orbimed Advisors LLC243K8.4%US$11.8MSep 30, 2026
BlackRock192K6.7%US$9.33MSep 30, 2026
Vanguard157K5.5%US$7.61MSep 30, 2026
Millennium137K4.8%US$6.64MSep 30, 2026
Ikarian Capital, LLC101K3.5%US$4.92MSep 30, 2026
Citadel90,6103.2%US$4.4MSep 30, 2026
Geode Capital66,7572.3%US$3.24MSep 30, 2026
Cable Car Capital, LP60,0002.1%US$2.91MSep 30, 2026
State Street59,0322.1%US$2.87MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Alyeska Investment Group, L.P.51,6711.8%US$2.51MSep 30, 2026
ADAR1 Capital Management, LLC51,6461.8%US$2.51MSep 30, 2026
Point72 Asset Management, L.P.44,2581.5%US$2.15MSep 30, 2026
Diadema Partners LP40,4351.4%US$1.96MSep 30, 2026
Eversept Partners, LP39,8401.4%US$1.94MSep 30, 2026
Carlyle Group Inc.38,6201.3%US$1.88MSep 30, 2026
Boothbay Fund Management, LLC35,1451.2%US$1.71MSep 30, 2026
Quinn Opportunity Partners LLC26,8100.93%US$1.3MSep 30, 2026
Rosalind Advisors, Inc.26,5170.92%US$1.29MSep 30, 2026
Knott David M Jr26,0850.91%US$1.27MSep 30, 2026
ExodusPoint Capital Management, LP22,0000.77%US$1.07MSep 30, 2026
Northern Trust19,9880.70%US$971KSep 30, 2026
XTX Topco Ltd19,6900.69%US$957KSep 30, 2026
Ameriprise18,8700.66%US$917KSep 30, 2026
Balyasny Asset Management L.P.12,1380.42%US$590KSep 30, 2026
Persistent Asset Partners Ltd10,3340.36%US$502KSep 30, 2026
Engineers Gate Manager LP9,6360.34%US$468KSep 30, 2026
Morgan Stanley9,2090.32%US$447KSep 30, 2026
Dimensional8,7880.31%US$426KSep 30, 2026
UBS7,9100.28%US$384KSep 30, 2026
Jane Street7,5490.26%US$367KSep 30, 2026
State Board Of Administration Of Florida Retirement System7,1820.25%US$349KSep 30, 2026
BNY6,8190.24%US$331KSep 30, 2026
Goldman Sachs6,7660.24%US$329KSep 30, 2026
Schwab6,0720.21%US$295KSep 30, 2026
Fidelity3,5890.12%US$174KSep 30, 2026
Rhumbline Advisers3,4530.12%US$168KSep 30, 2026
Nuveen2,5010.09%US$121KSep 30, 2026
DWS2,3230.08%US$113KSep 30, 2026
New York State Common Retirement Fund1,9000.07%US$92,302Sep 30, 2026
Tower Research Capital LLC (TRC)1,4400.05%US$69,956Sep 30, 2026
JPMorgan1,4110.05%US$66,698Sep 30, 2026
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.1,1920.04%US$57,907Sep 30, 2026
Barclays1,1500.04%US$55,868Sep 30, 2026
Lion Point Capital, LP1,0000.03%US$48,580Sep 30, 2026
Police & Firemen's Retirement System of New Jersey8640.03%US$41,973Sep 30, 2026
BNP Paribas6170.02%US$29,974Sep 30, 2026
Wells Fargo5530.02%US$26,865Sep 30, 2026
PNC Financial Services Group, Inc.3550.01%US$17,246Sep 30, 2026
RBC3150.01%US$15,000Sep 30, 2026

This page holds 50 of 67 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund84,9353.0%US$4.59MJun 30, 2026
iShares Russell 2000 ETF65,2222.3%US$3.52MJun 30, 2026
Vanguard Extended Market Index Fund31,8921.1%US$1.72MJun 30, 2026
Fidelity Small Cap Index Fund29,6941.0%US$1.27MJul 31, 2026
iShares Russell 2000 Value ETF16,8620.59%US$911KJun 30, 2026
iShares Micro-Cap ETF8,6650.30%US$468KJun 30, 2026
Schwab Small-Cap Index Fund6,7970.24%US$291KJul 31, 2026
iShares Russell 2000 Growth ETF6,2070.22%US$335KJun 30, 2026
Fidelity Extended Market Index Fund5,5660.19%US$285KMay 31, 2026
Master Small Cap Index Series4,8270.17%US$261KJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Dimensional U.S. Small Cap ETF3,7510.13%US$161KJul 31, 2026
Nuveen Small Cap Blend Index Fund3,6600.13%US$157KJul 31, 2026
Fidelity Small Cap Value Index Fund2,8370.10%US$153KJun 30, 2026
EQ/2000 Managed Volatility Portfolio2,7870.10%US$150KJun 30, 2026
LVIP State Street Small-Cap Index Fund2,1000.07%US$113KJun 30, 2026
U.S. Micro Cap Portfolio1,9680.07%US$84,289Jul 31, 2026
Fidelity Total Market Index Fund1,9200.07%US$98,438May 31, 2026
Fidelity Series Total Market Index Fund1,6520.06%US$84,698May 31, 2026
Goldman Sachs Small Cap Equity Insights Fund1,5510.05%US$66,429Jul 31, 2026
Small Cap Index Fund1,4190.05%US$76,626Jun 30, 2026
Vanguard Balanced Index Fund1,3450.05%US$72,630Jun 30, 2026
Global X Russell 2000 ETF1,2990.05%US$55,636Jul 31, 2026
State Street Small/Mid Cap Equity Index Portfolio1,2000.04%US$64,800Jun 30, 2026
Vanguard Institutional Total Stock Market Index Fund1,1590.04%US$62,586Jun 30, 2026
Tiff Multi-Asset Fund8320.03%US$44,928Jun 30, 2026
Fidelity Nasdaq Composite Index Fund8170.03%US$41,888May 31, 2026
iShares Russell Small/Mid-Cap Index Fund7680.03%US$32,893Jul 31, 2026
Small-Cap Index Portfolio7680.03%US$41,472Jun 30, 2026
Dimensional U.S. Core Equity 2 ETF6810.02%US$29,167Jul 31, 2026
Fidelity Small Cap Growth Index Fund6600.02%US$35,640Jun 30, 2026
Small Cap Index Trust6230.02%US$33,642Jun 30, 2026
EQ/Small Company Index Portfolio6100.02%US$32,940Jun 30, 2026
EQ/AB Small Cap Growth Portfolio6100.02%US$32,940Jun 30, 2026
NVIT Small Cap Index Fund6040.02%US$32,616Jun 30, 2026
1290 VT Micro Cap Portfolio5820.02%US$31,428Jun 30, 2026
ATM Small Cap Managed Volatility Portfolio5740.02%US$30,996Jun 30, 2026
NVIT GS Small Cap Equity Insights Fund4930.02%US$26,622Jun 30, 2026
Goldman Sachs Variable Insurance Trust Small Cap Equity Insights Fund4790.02%US$25,866Jun 30, 2026
DWS Small Cap Index VIP4250.01%US$22,950Jun 30, 2026
T. Rowe Price Small-Cap Index Fund4100.01%US$22,140Jun 30, 2026
Dimensional US Core Equity 1 ETF3710.01%US$15,890Jul 31, 2026
BlackRock Small Cap Index V.I. Fund3470.01%US$18,738Jun 30, 2026
SA Small Cap Index Portfolio3180.01%US$13,620Jul 31, 2026
U.S. Small Cap Portfolio3030.01%US$12,977Jul 31, 2026
1290 VT Small Cap Value Portfolio2940.01%US$15,876Jun 30, 2026
Victory Extended Market Index Fund264<0.01%US$11,307Jul 31, 2026
CVT Russell 2000 Small Cap Index Portfolio247<0.01%US$13,338Jun 30, 2026
Nationwide Small Cap Index Fund239<0.01%US$10,236Jul 31, 2026
Venerable Small Cap Index Fund217<0.01%US$11,718Jun 30, 2026
SmallCap Value Fund II170<0.01%US$7,281Jul 31, 2026

This page holds 50 of 68 holders. Open Shareholders

Big stakes

StakeStakeSharesDateFiling
Orin Hirschman9.10%250KJun 30, 2026Schedule 13G
BlackRock, Inc.6.80%188KJun 30, 2026Schedule 13G
Boone Peter David Mr6.40%68,184Nov 21, 2025Schedule 13G
Orbimed Advisors LLC5.60%162KSep 30, 2026Schedule 13G
AWM Investment Company, Inc.5.10%147KJun 30, 2026Schedule 13G
Carlyle Group Inc.4.70%50,893Feb 18, 2026Schedule 13D
HealthCap VIII, L.P.3.40%36,640Oct 7, 2025Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Michael Grey
Other companies: OnKure Therapeutics, Inc. (Director · Since at least Apr 8, 2021); Mirum Pharmaceuticals, Inc. (Director · Since at least Jul 17, 2019); Horizon Pharma PLC (Director · Sep 29, 2011 – May 3, 2018 · Past); BioMarin Pharmaceutical Inc. (Director · Dec 14, 2006 – Mar 5, 2021 · Past); Achillion Pharmaceuticals Inc (Director · Oct 25, 2006 – Dec 18, 2009 · Past); Idm Pharma Inc (Director · Jun 14, 2006 – Dec 11, 2008 · Past); SGX Pharmaceuticals Inc (President & CEO, Director · Jan 31, 2006 – Aug 20, 2008 · Past)
Executive Chairman, Director · Since at least Oct 8, 2020
Adrian Quartel
Other companies: Zevra Therapeutics, Inc. (Chief Medical Officer · Since at least Dec 6, 2024); Acer Therapeutics Inc (Chief Medical Officer · Feb 21, 2022 – Mar 14, 2023 · Past)
Chief Medical Officer · Since at least Jul 27, 2026
Bali Muralidhar
Other companies: Exicure, Inc. (Director · Jun 2, 2021 – Jun 13, 2022 · Past); OnKure Therapeutics, Inc. (Director · Apr 8, 2021 – Jun 6, 2023 · Past)
Director · Since at least Oct 8, 2020
Camilla V. Simpson
Other companies: GRI Bio, Inc. (Director · Since at least Apr 21, 2023)
Director · Since at least Oct 8, 2020
Moghrabi Dina Chaya
Other companies: Imago Biosciences Inc (Director · Jul 15, 2021 – Jan 11, 2023 · Past)
Director · Oct 8, 2020 – May 25, 2022 · Past
Samir Gharib
Other companies: Talon Therapeutics Inc (Controller, Direct. of Finance · Oct 17, 2011 – Jul 17, 2013 · Past)
President and Chief Financial Officer · Since at least Oct 8, 2020
Tiba Aynechi
Other companies: MBX Biosciences, Inc. (Director · Since at least Sep 12, 2024)
Director · Since at least May 22, 2024
Agnieszka JureckaVice President, Medical Affairs · Since at least Jun 22, 2026
Brian WallsVice President, Market Access · Since at least May 13, 2026
Bruno GagnonSenior Vice President, Clinical Development Operations · Since at least May 13, 2026
All 25 people
PersonSeat
Dale HooksChief Commercial Officer · Since at least Mar 9, 2026
Dan SpiegelmanIndependent · Since at least Nov 4, 2026
Darren JohnsonVice President, Commercial Operations · Since at least May 13, 2026
Dash ReddyVice President, Pharmaceutical Development and Manufacturing · Since at least Nov 4, 2026
Daven ModySenior Vice President, Regulatory and Quality · Since at least May 13, 2026
Eric JordanVice President, Marketing · Since at least Jun 15, 2026
Javier SzwarcbergCHIEF EXECUTIVE OFFICER, Director · Since at least Jun 30, 2026
Jessica Cohen PfefferVice President, Clinical Development · Since at least Aug 3, 2026
Jonas HanssonDirector · Oct 8, 2020 – Oct 14, 2020 · Past
Keli WalbertIndependent · Since at least Dec 15, 2025
Kirk WaysDirector · Since at least Oct 8, 2026
Percival Barretto-KoIndependent · Since at least Nov 5, 2026
Ralph William Charlton IIICHIEF MEDICAL OFFICER · Dec 14, 2023 – Dec 10, 2024 · Past
Saba SileSenior Vice President, Clinical Development · Since at least Oct 8, 2026
Tina GullottaVice President, Finance and Corporate Controller · Since at least Jun 15, 2026

Open People

Log in to ask 6ix AI your own questions about Spruce Biosciences, Inc.